These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1229 related items for PubMed ID: 26327569
1. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Wang Y, Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi X, Sun P, Huang HQ, Lin TY, Guan ZZ, Li ZM. Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569 [Abstract] [Full Text] [Related]
8. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD. J Clin Oncol; 2011 Apr 10; 29(11):1452-7. PubMed ID: 21383296 [Abstract] [Full Text] [Related]
13. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z. Ann Hematol; 2012 Jun 10; 91(6):837-45. PubMed ID: 22160255 [Abstract] [Full Text] [Related]
14. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. J Clin Oncol; 2014 Dec 10; 32(35):3996-4003. PubMed ID: 25385729 [Abstract] [Full Text] [Related]
15. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M. Am J Hematol; 2013 Apr 10; 88(4):273-6. PubMed ID: 23460351 [Abstract] [Full Text] [Related]
16. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. Mian M, Augustin F, Kocher F, Gunsilius E, Willenbacher W, Zabernigg A, Zangerl G, Oexle H, Schreieck S, Schnallinger M, Fiegl M. Anticancer Res; 2014 May 10; 34(5):2559-64. PubMed ID: 24778077 [Abstract] [Full Text] [Related]